Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310

ANTABIO Announces Appointment of Dr. Erick Lelouche as Chairman of the Board

ANTABIO Raises €25 million in Series B Financing

Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections

Launch of ARPEGE, a French multidisciplinary consortium to fight antibiotic resistance through preventive, diagnostic, therapeutic and economic approaches

Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

Antabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation for MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients

Antabio applauds the new mechanism for reimbursement of antibiotics set up by CMS in the US

Antabio Receives QIDP Designation from the U.S. FDA for the Development of Its Metallo Beta-Lactamase inhibitor ANT2681